---
document_datetime: 2024-10-09 09:48:10
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/amlodipine-valsartan-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: amlodipine-valsartan-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.4643996
conversion_datetime: 2025-12-27 15:46:37.29032
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Amlodipine-Valsartan Mylan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                  |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------|
| N/0023               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                | 08/10/2024                          |                                             | PL                               |                                          |
| II/0021              | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of | 05/09/2024                          | n/a                                         |                                  | Submission of an updated RMP version 4.0 |

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | which require to be further substantiated new additional data to be submitted by the MAH significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             | change(s) by where   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------|
| IAIN/0022 | B.II.a.3.a.1 - Changes in the composition (excipients) of the finished product - Changes in components of the flavouring or colouring system - Addition , deletion or replacement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 23/07/2024 |            | SmPC and PL |                      |
| N/0020    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 14/08/2023 | 15/09/2023 | PL          |                      |
| IA/0019/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 17/05/2023 | n/a        |             |                      |

<div style=\"page-break-after: always\"></div>

|           | deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                      |            |            |                        |                                                                                                                                                                                                                                            |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0018 | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority           | 29/09/2022 | 15/09/2023 | Annex II               | To update Annex II in line with the outcome of the Article 31 referral on angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (EMEA/H/A-31/1471) and Article 5(3) assessment on nitrosamines (EMEA/H/A- 5(3)/1490). |
| IB/0017   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation      | 24/08/2022 | 15/09/2023 | SmPC and PL            |                                                                                                                                                                                                                                            |
| IB/0014   | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition) | 06/06/2022 | n/a        |                        |                                                                                                                                                                                                                                            |
| N/0015    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                    | 03/06/2022 | 15/09/2023 | PL                     |                                                                                                                                                                                                                                            |
| IB/0011   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                       | 04/11/2021 | n/a        |                        |                                                                                                                                                                                                                                            |
| T/0012    | Transfer of Marketing Authorisation                                                                                                                                                                 | 12/08/2021 | 15/09/2021 | SmPC, Labelling and PL |                                                                                                                                                                                                                                            |
| IAIN/0010 | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                          | 29/06/2021 | 15/09/2021 | Annex II               |                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|          | authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |          |                                                                                                 |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------------------------------------------------------|
| A31/0004 | The European Commission triggered a referral under Article 31 of Directive 2001/83/EC and requested the CHMP to assess the impact of nitrosamine impurities on the benefit-risk balance of valsartan-containing medicinal products and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked. During the CHMP plenary meeting in September 2018, the scope of the referral has been widened to include all sartans with a tetrazole group in their molecular structure (candesartan, irbesartan, losartan, olmesartan and valsartan). The CHMP Opinion was issued on 31 January 2019 and the Commission Decision was issued on 17 April 2019. In a letter dated 29 July 2020, the European Commission requested the EMA to assess the impact of the outcome of the Article 5(3) assessment on nitrosamines adopted on 25 June 2020 on the CHMP's opinion of 31 January 2019 for the scientific assessment and review under Article 31 of Directive 2001/83/EC regarding angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (EMEA/H/A-31/1471). The CHMP was requested to give its recommendation whether the conditions of the Marketing Authorisations should be varied. | 12/11/2020 | 12/02/2021 | Annex II | Please refer to the assessment report: Amlodipine-Valsartan Mylan EMEA/H/A- 31/1471/C/4037/0004 |

<div style=\"page-break-after: always\"></div>

| IA/0009/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                          | 02/02/2021   | n/a        |                                  |                                                                                                                                                                                                                                                                                          |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0008      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                     | 12/11/2020   | 14/01/2021 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Amlodipine-Valsartan Mylan in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0007/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.2.c.1 - Change to importer, batch release | 21/02/2020   | 14/01/2021 | Annex II and PL                  |                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | responsible for importation and/or batch release - Not including batch control/testing B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)          |            |            |                        | Replacement or   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------|
| IB/0006/G | This was an application for a group of variations. B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate an already approved manufacturer | 06/09/2019 | n/a        |                        | from             |
| N/0005    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                | 11/03/2019 | 14/01/2021 | PL                     |                  |
| IB/0003   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                  | 26/02/2018 | 25/02/2019 | SmPC, Labelling and PL |                  |

<div style=\"page-break-after: always\"></div>

| IAIN/0002   | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/11/2016   | 13/10/2017   | SmPC and PL   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|
| IAIN/0001/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - | 12/08/2016   | n/a          |               |

<div style=\"page-break-after: always\"></div>

| control/testing takes place   |
|-------------------------------|